Many on staff have personally used GLP1 medication, which helps them better relate to patients
B.HauskeS
Dit omdat per persoon verschilt hoeveel carnitine het lichaam kan aanmaken uit de aminozuren L-lysine en L-methionine
European research institutions frequently employ peptide blends when studying complex molecular signalling networks that require simultaneous peptide-driven inputs
What the study found In patients with obesity + HFpEF, semaglutide and tirzepatide showed similar rates of: all-cause death HF hospitalization and the composite outcome (death + HF hospitalization) Key numbers TriNetX federated EHR analysis 3,983 patients total 1:1 propensity-matched: 1,258 vs 1,258 Median follow-up: 24 weeks Primary composite outcome: HR 1.14 (95% CI 0.891.46), p=0.286 My take For cardio-obesity HFpEF care, this is a useful reminder: Drug selection is often aboutthe right patient, the right goal, the right contextnot just which agent gives more weight loss. So in practice, choice may be driven by: tolerability access/cost glycaemic needs comorbidities patient adherence preferences Important caveat: this is retrospective observational EHR data (not a randomized head-to-head trial), with short follow-up
VD modulates neuroinflammation by suppressing TLR/NF-B signaling, reducing pro-inflammatory cytokines (IL-1 and TNF-) while simultaneously enhancing neurotrophin expression (BDNF and NT-3) and stabilizing calcium homeostasis through L-type channel regulation
